41542-10-3

Basic information

• Product Name: N-[(2,6-dichlorophenyl)carbamothioyl]benzamide
• Synonyms: benzamide, N-[[(2,6-dichlorophenyl)amino]thioxomethyl]-; N-[(2,6-Dichlorophenyl)carbamothioyl]benzamide; N-benzoyl-N'-(2,6-dichlorophenyl)thiourea
• CAS NO: 41542-10-3
• Molecular Formula: C₁₄H₁₀Cl₂N₂OS
• Molecular Weight: 325.213
• Mol File: 41542-10-3.mol
• Article Data: 6

Chemical Properties

• Density: 1.461g/cm³
• Refractive Index: 1.701
• CAS DataBase Reference: N-[(2,6-dichlorophenyl)carbamothioyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(2,6-dichlorophenyl)carbamothioyl]benzamide(41542-10-3)
• EPA Substance Registry System: N-[(2,6-dichlorophenyl)carbamothioyl]benzamide(41542-10-3)

Safety Data

• Hazardous Substances Data: 41542-10-3(Hazardous Substances Data)

Upstream product

• 532-55-8 Benzoyl isothiocyanate 
• 608-31-1 2,6-Dichloroaniline 
• 98-88-4 benzoyl chloride 
• 65-85-0 benzoic acid 

Downstream Products

• 27806-81-1 2,6-Dichlorphenyl-S-methylisothioharnstoff 
• 82636-21-3 1-(2,6-Dichloro-phenyl)-2-methylsulfanyl-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester 
• 81502-96-7 1-(2,6-dichlorophenyl)-2-benzoyl-3-tetrahydropyranyloxyguanidine 
• 6590-91-6 1-(2,6-dichlorophenyl)thiourea 

Relevant articles and documents

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).

Solution-phase microwave assisted parallel synthesis of N,N′-disubstituted thioureas derived from benzoic acid: Biological evaluation and molecular docking studies

An efficient and facile microwave-assisted solution phase parallel synthesis for a 26-member library of N,N′-disubstituted thiourea analogs were accomplished successfully. The reaction time for synthesis of analogs was drastically reduced from a reported 8-12 h to only 10 min. Compounds were more than 95% pure, as characterized by modern analytical techniques, i.e. 1H & 13C NMR and FT-IR. The solid phase structural analysis has also been performed by single crystal XRD analysis. Synthesized compounds were preliminary screened for their in vitro urease inhibition and antifungal activity. Most of the compounds were found to be potent inhibitors of urease. However, the most significant activity was found for 11 with IC 50 of 1.67 μM. The docking scores correlate with the IC 50 values of inhibitors.

Synthesis & Pharmacological Evaluation of Ethyl 3-Substituted-phenyl-2-methylmercapto/ phenyl/ methyl-4(3H)-pyrimidone-5-carboxylates

A number of ethyl 3-substituted-phenyl-2-methylmercapto/ phenyl/ methyl-4(3H)-pyrimidone-5-carboxylates (V) have been prepared by the reaction of amidines (III) with diethyl ethoxymethylenemalonate.In order to confirm the structure (V), ethyl 3-(2'-methylphenyl)-2-methylmercapto-4(3H)pyrimidone-5-carboxylate (103) has been transformed into the earlier synthesised 3-(2'-methylphenyl)-2-methylmercapto-4(3H)-pyrimidone (115) by decarboxylation of 3-(2'-methylphenyl)-2-methylmercapto-4(3H)-pyrimidone-5-carboxylic acid (114), obtained by the alkaline hydrolysis of 103.Someof these compounds have shown antiinflammatory, diuretic and antipassive cutaneous anaphylaxis activities.